Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed

Int J Dermatol. 2018 Apr;57(4):493-494. doi: 10.1111/ijd.13882. Epub 2018 Jan 23.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • 2-Naphthylamine
  • Adrenal Cortex Hormones / therapeutic use
  • Anilides / adverse effects
  • Anilides / therapeutic use
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Carbamates / adverse effects
  • Carbamates / therapeutic use
  • Cyclopropanes
  • Drug Eruptions / drug therapy
  • Drug Eruptions / epidemiology*
  • Drug Eruptions / etiology*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hepacivirus / drug effects*
  • Hepacivirus / isolation & purification
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy*
  • Histamine Antagonists / therapeutic use
  • Humans
  • Incidence
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / adverse effects
  • Macrocyclic Compounds / therapeutic use
  • Male
  • Proline / analogs & derivatives
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Treatment Outcome
  • Uracil / adverse effects
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Valine

Substances

  • Adrenal Cortex Hormones
  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Histamine Antagonists
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • Ritonavir
  • paritaprevir